This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Thomas R. Tice, PhD
Senior Director, Global Strategic and Technical Marketing at Evonik Corporation, Health Care


Dr. Tice has 44 years’ experience developing bioabsorbable injectables for long-acting drug delivery. His primary expertise includes long-acting, injectable microparticle formulations, bioabsorbable lactide/glycolide polymers, and microencapsulation and nanoencapsulation processes. He holds 49 US patents with many foreign equivalents and has more than 180 publications, presentations and invited lectures to his credit. He led the team and is one of the inventors that developed the first commercial, injectable, long-acting microparticle product. He has served with United States Pharmacopeia for 18 years, presently serving on the General Chapters-Dosage Forms Expert Committee and several subcommittees including the Nanotechnology Joint Subcommittee and LG Polymer Joint Subcommittee.

Agenda Sessions

  • Long-Acting Peptide Delivery: Success of Bioabsorbable Microparticle Products and the Future of Bioabsorbable Nanoparticles